Serum perfluoroalkyl acids concentrations and memory impairment in a large cross-sectional study

BMJ Open

Volumn 3, Issue 6, 2013, Pages

  Gallo, Valentina ^a,b   Leonardi, Giovanni ^a   Brayne, Carol ^c   Armstrong, Ben ^a   Fletcher, Tony ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PERFLUOROHEXANE SULFONATE; PERFLUORONONANOIC ACID; PERFLUOROOCTANATE; PERFUOROOCTANE SULFONATE; POLYMER; UNCLASSIFIED DRUG;

ADULT; AGED; AMNESIA; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SHORT TERM MEMORY;

EID: 84878760126     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002414     Document Type: Article

References (42)

1. Kato K, Wong LY, Jia LT, et al. Trends in exposure to polyfluoroalkyl chemicals in the U.S. population: 1999-2008 (dagger). Environ Sci Technol 2011;45:8037-45.
2. Tao L, Kannan K, Kajiwara N, et al. Perfluorooctanesulfonate and related fluorochemicals in albatrosses, elephant seals, penguins, and polar skuas from the Southern Ocean. Environ Sci Technol 2006;40:7642-8. (Pubitemid 46012558)
3. Kim SK, Lee KT, Kang CS, et al. Distribution of perfluorochemicals between sera and milk from the same mothers and implications for prenatal and postnatal exposures. Environ Pollut 2011;159:169-74.
4. Lau C, Anitole K, Hodes C, et al. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 2007;99:366-94. (Pubitemid 351753056)
5. D'Hollander W, de Voogt P, De Coen W, et al. Perfluorinated substances in human food and other sources of human exposure. Rev Environ Contam Toxicol 2010;208:179-215.
6. Goosey E, Harrad S. Perfluoroalkyl compounds in dust from Asian, Australian, European, and North American homes and UK cars, classrooms, and offices. Environ Int 2011;37:86-92.
7. DeWitt JC, Shnyra A, Badr MZ, et al. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit Rev Toxicol 2009;39:76-94.
8. Peters JM, Gonzalez FJ. Why toxic equivalency factors are not suitable for perfluoroalkyl chemicals. Chem Res Toxicol 2011;24:1601-9.
9. Howroyd P, Swanson C, Dunn C, et al. Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha). Toxicol Pathol 2004;32:591-9. (Pubitemid 39258464)
10. Capri M, Salvioli S, Sevini F, et al. The genetics of human longevity. Ann N Y Acad Sci 2006;1067:252-63. (Pubitemid 43810006)
11. Paolisso G, Barbieri M, Rizzo MR, et al. Low insulin resistance and preserved beta-cell function contribute to human longevity but are not associated with TH-INS genes. Exp Gerontol 2001;37:149-56. (Pubitemid 33152706)
12. Heneka MT, Feinstein DL, Galea E, et al. Peroxisome proliferator- activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J Neuroimmunol 1999;100:156-68. (Pubitemid 30038249)
13. Heneka MT, Klockgether T, Feinstein DL. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 2000;20:6862-7.
14. Combs CK, Johnson DE, Karlo JC, et al. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000;20:558-67. (Pubitemid 30225558)
15. Kim EJ, Kwon KJ, Park JY, et al. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res 2002;941:1-10. (Pubitemid 34603279)
16. Luna-Medina R, Cortes-Canteli M, Alonso M, et al. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem 2005;280:21453-62. (Pubitemid 40805710)
17. Whitehead JP. Diabetes: new conductors for the peroxisome proliferator-activated receptor gamma (PPARgamma) orchestra. Int J Biochem Cell Biol 2011;43:1071-4.
18. Takacs ML, Abbott BD. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol Sci 2007;95:108-17. (Pubitemid 44942782)
19. Power MC, Webster TF, Baccarelli AA, et al. Cross-sectional association between polyfluoroalkyl chemicals and cognitive limitation in the national health and nutrition examination survey. Neuroepidemiology 2012;40:125-32.
20. McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet 2012;379:2291-9.
21. MacNeil J, Steenland NK, Shankar A, et al. A cross-sectional analysis of type II diabetes in a community with exposure to perfluorooctanoic acid (PFOA). Environ Res 2009;109:997-1003.
22. Steenland K, Fletcher T, Savitz DA. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ Health Perspect 2010;118:1100-8.
23. Lin CY, Chen PC, Lin YC, et al. Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. Diabetes Care 2009;32:702-7.
24. Lundin JI, Alexander BH, Olsen GW, et al. Ammonium perfluorooctanoate production and occupational mortality. Epidemiology 2009;20:921-8.
25. Frisbee SJ, Brooks AP Jr, Maher A, et al. The C8 health project: design, methods, and participants. Environ Health Perspect 2009;117:1873-82.
26. Steenland K, Jin C, MacNeil J, et al. Predictors of PFOA levels in community surrounding a chemical plant. Environ Health Perspect 2009;117:1083-8.
27. Kuklenyik Z, Reich JA, Tully JS, et al. Automated solid-phase extraction and measurement of perfluorinated organic acids and amides in human serum and milk. Environ Sci Technol 2004;38:3698-704. (Pubitemid 38879911)
28. Gallo V, Egger M, McCormack V, et al. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement. PLoS Med 2011;8:e1001117.
29. Gallo V, Leonardi G, Genser B, et al. Serum perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) concentrations and liver function biomarkers in a population with elevated PFOA exposure. Environ Health Perspect 2012;120:655-60.
30. Lleo A, Galea E, Sastre M. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 2007;64:1403-18. (Pubitemid 46889230)
31. Alafuzoff I, Overmyer M, Helisalmi S, et al. Lower counts of Astroglia and activated Microglia in patients with Alzheimer's disease with regular use of non-steroidal anti-inflammatory drugs. J Alzheimer's Dis 2000;2:37-46. (Pubitemid 30353516)
32. Jimenez S, Baglietto-Vargas D, Caballero C, et al. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer 's disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci 2008;28:11650-61.
33. Revill P, Moral MA, Prous JR. Impaired insulin signaling and the pathogenesis of Alzheimer's disease. Drugs Today (Barc) 2006;42:785-90.
34. Anbalagan M, Huderson B, Murphy L, et al. Post-translational modifications of nuclear receptors and human disease. Nucl Recept Signal 2012;10:e001.
35. Choi JH, Banks AS, Estall JL, et al . Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010;466:451-6.
36. Hauser S, Adelmant G, Sarraf P, et al. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 2000;275:18527-33. (Pubitemid 30414814)
37. Wolf CJ, Takacs ML, Schmid JE, et al. Activation of mouse and human peroxisome proliferator-activated receptor alpha by perfluoroalkyl acids of different functional groups and chain lengths. Toxicol Sci 2008;106:162-71.
38. Johansson N, Eriksson P, Viberg H. Neonatal exposure to PFOS and PFOA in mice results in changes in proteins which are important for neuronal growth and synaptogenesis in the developing brain. Toxicol Sci 2009;108:412-18.
39. Johansson N, Fredriksson A, Eriksson P. Neonatal exposure to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) causes neurobehavioural defects in adult mice. Neurotoxicology 2008;29:160-9.
40. Viberg H, Lee I, Eriksson P. Adult dose-dependent behavioral and cognitive disturbances after a single neonatal PFHxS dose. Toxicology 2013;304:185-91.
41. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005;54:2460-70. (Pubitemid 41134276)
42. Ferri CP, Prince M, Brayne C, et al. Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-7. (Pubitemid 41797645)